Ana I. Stancic, C.P.A., M.B.A.
— Chief Operating Officer, Principal Executive Officer, Executive Vice President and Chief Financial Officer
Ana I. Stancic was promoted to Principal Executive Officer, Chief Operating Officer and Executive Vice President, effective October 17, 2011. Ms. Stancic joined Enzon in June of 2011 as Senior Vice President, Finance and Chief Financial Officer. Most recently, Ms. Stancic served as senior vice president and chief financial officer of M2Gen, a wholly owned for-profit subsidiary of Moffitt Cancer Center. Prior to that, she served as chief financial officer at Aureon Biosciences, Inc. From 2007 to 2008, she was executive vice president and chief financial officer at Omrix Biopharmaceuticals, Inc., which was acquired by Johnson & Johnson. From 2004 to 2007, Ms. Stancic was at ImClone Systems, Inc., which was acquired by Eli Lilly, Inc. At ImClone, she served in various leadership roles, including senior vice president of finance. Prior to joining ImClone, she was vice president and controller at Savient Pharmaceuticals, Inc. Ms. Stancic began her career at PricewaterhouseCoopers in the Assurance practice, where she had responsibility for international and national companies in the pharmaceutical and services industries.
Ms. Stancic is a certified public accountant and holds an M.B.A. from Columbia University Graduate School of Business. She currently serves as a member of the Board of Directors of Champions Oncology, Inc., KV Pharmaceutical and Genta Incorporated.
Charles Conover, Ph.D., M.B.A.
— Senior Vice President, Research and Development, Program Management
Charles Conover has served as senior vice president of research & development, program management since January 2012. Previously, Dr. Conover served in several senior roles in global project and alliance management, scientific affairs, and experimental therapeutics after first joining Enzon as a scientist in 1993.
Dr. Conover has authored more than 30 full-length articles and has received multiple awards for his contributions to research and development at Enzon. He is a member of the Project Management Institute, the Drug Information Association, the American Association for Cancer Research, and the Controlled Release Society. He holds Ph.D. in physiology and an M.B.A. in management of innovation and technology from Rutgers University.
Aby Buchbinder, M.D.
— Vice President, Clinical Development
Aby Buchbinder has served as Enzon’s vice president of clinical development since January 2006. Prior to joining Enzon, he held several clinical-development positions at major pharmaceutical companies, including senior director at Johnson & Johnson PRD, global clinical director at Aventis, and associate director at Pharmacia Corporation. Dr. Buchbinder has experience with the design, writing, and implementation of clinical protocol; the design, defense and implementation of clinical development plans; leadership of global clinical teams; and interactions with regulatory authorities.
Prior to joining industry, Dr. Buchbinder was head of the Stem Cell Transplantation Program at North Shore University Hospital in Manhasset, NY, where he was a practicing medical oncologist. He received his M.D. from McGill University.
Andrew Rackear, J.D.
— Vice President and General Counsel
Andrew Rackear has served as Enzon’s general counsel and secretary since April 2010, and also as chief compliance officer since September 2010. Prior to joining Enzon, Mr. Rackear served as senior vice president and general counsel for NPS Pharmaceuticals, and vice president and general counsel for Chugai Pharma USA and Amersham Biosciences Corp, where he also served as president of North American operations.
Prior to joining the industry, Mr. Rackear engaged in litigation and commercial law practice at Marks & Murase (now Bingham McCutchen) and served as associate general counsel at Sharp Electronics Corp. Mr. Rackear holds a J.D. from New York University School of Law.
Timothy G. Daly
— Vice President, Controller and Chief Accounting Officer
Tim Daly has served as Enzon’s vice president, controller and chief accounting officer since December 2011. Mr. Daly has over 12 years of experience in the biotech and pharmaceutical healthcare industries. Prior to joining Enzon, Mr. Daly served as director of finance at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. During his tenure with ImClone Sytems, Tim served in various operational and financial roles, including treasury and cash management, compliance and internal controls.
Mr. Daly holds a B.A.S. in accounting from Rider University